Novel immunologic approaches to the management of malignant melanoma

Current Opinion in Oncology

Volumn 13, Issue 2, 2001, Pages 124-128

  Weber, Jeffrey S ^a   Aparicio, Ana ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELANOMA VACCINE; TUMOR ANTIGEN; TUMOR VACCINE;

ADVANCED CANCER; ANTIGEN RECOGNITION; IMMUNOREACTIVITY; IMMUNOTHERAPY; MELANOMA; METASTASIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS; GENES, MHC CLASS I; GENES, MHC CLASS II; HUMANS; IMMUNOTHERAPY; MELANOMA; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SUBUNIT;

EID: 0035079607     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200103000-00007     Document Type: Review

References (50)

1. The treatment of malignant tumors by repeated inoculations of erysipelas: With a report of ten original cases. 1893
2. Spontaneous regression of subcutaneous metastasis of cutaneous melanoma
3. Vitiligo in patients with metastatic melanoma: A good prognostic sign
4. Prognostic significance of hypopigmentation in malignant melanoma
5. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
6. Results of interleukin-2-based treatment in advanced melanoma: A case record-based analysis of 631 patients
7. Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells: Analysis of specificity and mechanisms of interaction
8. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas
9. Peptide-induced antiviral protection by cytotoxic T cells
10. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide
11. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells
12. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A
13. Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay
14. Immunization of patients with melanoma peptide vaccines: Immunologic assessment using the ELISPOT assay
15. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression
16. Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination
17. Human tumor antigens recognized by T lymphocytes
18. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
19. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection
20. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes
21. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
22. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes
23. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
24. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen
25. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma
26. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes
27. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
28. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma
29. Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions
30. Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: Implications for immunotherapy
31. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo
32. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: Implications for tumor vaccines with melanoma-associated antigens
33. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: Evidence for immunoselection of antigen-loss variants in vivo
34. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection
35. Differential expression of MART-1 in primary and metastatic melanoma lesions
36. Immune selection after antigen-specific immunotherapy of melanoma
37. Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma
38. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides
39. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
40. Tolerance, danger, and the extended family
41. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo
42. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine
43. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma
44. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
45. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
46. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
47. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides
48. Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway
49. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations
50. A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma